Stoke TherapeuticsSTOK
STOK
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
9% more funds holding
Funds holding: 118 [Q3] → 129 (+11) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
10% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 42
1.33% less ownership
Funds ownership: 110.93% [Q3] → 109.61% (-1.33%) [Q4]
11% less capital invested
Capital invested by funds: $718M [Q3] → $640M (-$77.4M) [Q4]
86% less call options, than puts
Call options by funds: $38K | Put options by funds: $263K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
252%
upside
Avg. target
$31
396%
upside
High target
$47
652%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein 28% 1-year accuracy 102 / 358 met price target | 652%upside $47 | Buy Reiterated | 19 Mar 2025 |
Chardan Capital Rudy Li 0% 1-year accuracy 0 / 3 met price target | 284%upside $24 | Buy Maintained | 19 Mar 2025 |
Needham Joseph Stringer 0% 1-year accuracy 0 / 5 met price target | 252%upside $22 | Buy Reiterated | 18 Mar 2025 |
Financial journalist opinion
Based on 6 articles about STOK published over the past 30 days
Neutral
Business Wire
1 day ago
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the 24th Annual Needham Virtual Healthcare Conference on Tues.
Negative
Investopedia
2 weeks ago
Stoke Therapeutics Stock Slips as CEO Steps Down
Shares of Stoke Therapeutics (STOK) slipped Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.
Negative
Zacks Investment Research
2 weeks ago
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago.
Neutral
Business Wire
2 weeks ago
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the full year ended December 31, 2024 and provided business updates. “Recent milestones – including Breakt.
Neutral
Business Wire
2 weeks ago
Stoke Therapeutics Announces CEO Transition
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today the Company announced that Edward M. Kaye, M.D., has decided to step down from his role as Chief Executive Officer effective as of March 19, 2025. To.
Positive
Zacks Investment Research
2 weeks ago
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
1 month ago
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference Date: Wednesday, March 5, 2025 Time: 9:50 a.m. ET Leerink Partners Global Healthcare Conference Date: Monday, March 10, 2025 Time: 10:40 a.m. ET Live webcasts of each ev.
Positive
Market Watch
1 month ago
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.
Neutral
Business Wire
1 month ago
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying c.
Neutral
GlobeNewsWire
1 month ago
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and is eligible to receive up to $385M in milestones as well as royalties CAMBRIDGE, Mass. and BEDFORD, Mass.
Charts implemented using Lightweight Charts™